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INTRODUCTION 
The introduction of general anesthetics into clinical practice over 
150 years ago stands as one of the pioneering innovations of medicine. 
This single invention facilitated the development of modern surgery and 
spawned the speciality of anesthesiology. General anesthesia can broadly 
be defined as a drug-induced reversible depression of the central nervous 
system resulting in the loss of response to and perception of all external 
stimuli. General anesthesia is a dynamic balance between the level of 
hypnosis, analgesia, and stimulation. It is usually defined as a triad of 
amnesia, analgesia, and muscle relaxation. 
Inhalation anesthetics are the most common drugs used for the 
provision of general anesthesia. Adding only a fraction of a volatile 
anesthetic to the inspired oxygen results in a state of unconsciousness and 
amnesia. When combined with intravenous adjuvants, opioids and 
benzodiazepines, a balanced anesthetic technique
1
 is achieved that results 
in analgesia, further sedation or hypnosis, and amnesia. The popularity of 
the inhaled anesthetics for surgical procedures is because of their ease of 
administration and the ability to reliably monitor their effects with both 
clinical signs and end-tidal concentrations.  
2 
 
Inhaled volatile anesthetics remain the most widely used drugs for 
maintenance of general anesthesia because of their predictable 
intraoperative and recovery characteristics. Management of 
haemodynamic stability and early recovery is the most important part of a 
standardized balanced technique. Rapid induction and recovery may lead 
to faster operating room turnover times, shorter recovery room stays, and 
earlier discharges to home. 
Thyroidectomy is the most common endocrine surgical procedure 
being carried out throughout the world. Maintenance of anesthesia during 
thyroidectomy deals with making the patient unaware of the severe 
stimulation and also by providing excellent analgesia and immobility. 
Blunting of the stimulation and awareness is made possible by the 
volatile anesthetics. Also it potentiates the action of neuromuscular 
blocking agents there by reducing the dose required for providing 
immobility. An ideal general anesthetic technique should provide smooth 
and rapid induction, optimal operating conditions, and rapid recovery 
with minimal or no side effects.
2
  
Inhaled anesthetics allow rapid emergence from anesthesia because 
of easy titratability, with inherent neuromuscular blocker potentiating 
effects . The availability of less soluble inhalation anesthetics such as 
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sevoflurane and desflurane made us rethink about the selection of volatile 
anesthetics for surgical procedures. Given the low solubility and low 
blood: gas partition coefficient of sevoflurane and desflurane, faster 
induction and emergence from anesthesia is expected compared to 
traditional inhalation anesthetics.
3
  
The purpose of this study was to compare the sevoflurane and 
desflurane
 
in terms of intraoperative hemodynamic, postoperative 
emergence and recovery characteristics. 
  
AIMS
AND
OBJECTIVES
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AIM OF STUDY 
To compare the intraoperative hemodynamic stability and post-
operative recovery characteristics of sevoflurane with those of desflurane 
in nitrous oxide anaesthesia for elective Thyroid surgeries 
 
OBJECTIVES 
1. To determine the change in Heart rate and Mean Arterial Pressure 
with each inhalation agent 
2. To compare recovery time after discontinuation of the inhaled 
agent , by noting the time of first spontaneous movement, time to 
response to pain, time to extubation, time to recall of name, time to 
hand grip and time to achieve Post Anaesthesia Recovery Score 
(PARS) of Aldrete and Kroulik ≥ 10. 
  
REVIEW
OF
LITERATURE
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REVIEW OF LITERATURE 
Ravi Jindal
14
 et al did a study on comparison of maintenance and 
emergence characteristics after desflurane or sevoflurane in outpatient 
anesthesia. They found that the time from administration of reversal agent 
to response to painful stimuli, to eye opening, to verbal commands and 
spontaneous eye opening were significantly shorter in patients given 
desflurane than in patients given sevoflurane. For a given duration of 
anesthesia, emergence from anesthesia was significantly faster in 
desflurane compared to sevoflurane group. They concluded that both 
sevoflurane and desflurane provide a similar time to home readiness 
despite a faster wake up time with desflurane.
 
Earl M. Strum
15
 et al compared postoperative recovery after 
desflurane versus sevoflurane anesthesia in morbidly obese adults who 
underwent gastrointestinal bypass surgery via an open laparotomy. The 
time from discontinuation of volatile anesthetic administration to eye 
opening, squeezing hand, tracheal extubation and orientation were 
significantly shorter in patients given desflurane than in patients given 
sevoflurane. They concluded that morbidly obese adult patients who 
underwent major abdominal surgery in a prospective, randomised study 
awoke significantly faster after desflurane than after sevoflurane 
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anesthesia and the patients anesthetised with desflurane had higher 
oxygen saturation on entry to the PACU.
 
Rachel Eshima Mckay
16
 et al studied whether the airway reflexes 
return more rapidly after desflurane anesthesia than after sevoflurane 
anesthesia. They found that the time from stopping the anesthetic 
administration to appropriate response to command was longer in 
sevoflurane than desflurane. In addition, they found that the time from 
first response to command to ability to swallow 20ml of water without 
coughing or drooling was longer after sevoflurane. They concluded that 
restoration of protective airway reflexes occurs significantly sooner after 
anesthesia with desflurane than after anesthesia with sevoflurane.
 
Gupta A
17
 et al did a study on comparison of recovery profile after 
ambulatory anesthesia with propofol, isoflurane, sevoflurane and 
desflurane. They found no differences in early recovery between propofol 
and isoflurane. Early recovery was faster with desflurane compared with 
propofol and isoflurane and with sevoflurane compared with isoflurane. 
A minor difference was found in home readiness between sevoflurane 
and isoflurane but not among the other anesthetics. They concluded that 
comparing postoperative recovery after propofol, isoflurane, desflurane 
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and sevoflurane-based anesthesia in adults demonstrated early recovery 
was faster in the desflurane and sevoflurane groups.
 
S Gergin
13
 et al conducted a study to compare the haemodynamic, 
emergence and recovery characteristics of sevoflurane with those of 
desflurane in nitrous oxide anesthesia in forty patients undergoing general 
surgery. They found out that time to extubation, recall of name and 
handgrip on command and achieving PARS (Post Anesthesia Recovery 
Score of Aldrete and Kroulik) ≥ 10 were shorter in the desflurane group, 
where as the hemodynamic stability remained similar in both groups. 
They concluded that, desflurane, like sevoflurane, maintains 
haemodynamic stability during intraoperative period, but early recovery 
profile was rapid in desflurane group.
 
J Dupont
18
 et al studied the maintenance and recovery profiles after 
general anesthesia with sevoflurane, desflurane, and isoflurane in 100 
patients undergoing pulmonary surgery. The anesthetics had comparable 
hemodynamic effects and arterial oxygenation during one-lung 
ventilation. They observed that emergence was twice more fast with 
desflurane than with sevoflurane or isoflurane. Early recovery was also 
more rapid after desflurane. They concluded that in pulmonary surgery, 
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desflurane, but not sevoflurane, allowed more rapid emergence and 
earlier recovery than isoflurane.
 
L. La Colla
19
 et al did a study to compare desflurane vs. 
sevoflurane kinetics and dynamics in morbidly obese patients and their 
recovery profile when no premedication had been used. Patients in the 
desflurane group reported early recovery times compared with those of 
sevoflurane group. They found that the time from discontinuation of the 
anesthetic drug to eye opening after verbal command, squeezing the 
observer’s hand, extubation and ability to state their name and give their 
correct date of birth were all significantly shorter in desflurane group 
with p value less than 0.001. The time from the discontinuation of the 
anesthetic drug to discharge from the recovery room was also 
significantly shorter in the desflurane group. (p<0.001). They concluded 
that desflurane provides faster wash-in and wash-out than sevoflurane in 
morbidly obese patients, and recovery is much faster after desflurane 
administration when no premedication has been used.
 
Pensado Castineiras A
20
 et al compared the anesthetic maintenance 
and early postoperative recovery and psychomotor function in patients 
who have been anesthetised with desflurane, sevoflurane or isoflurane 
during prolonged open urological surgery. They found that the recovery 
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times in the operating room were significantly shorter after anesthesia 
with desflurane and sevoflurane than with isoflurane, with no significant 
differences between the desflurane and sevoflurane groups. They 
concluded that desflurane and sevoflurane demonstrated advantages over 
isoflurane during recovery from anesthesia in the operating theatre. No 
significant differences were found in psychomotor recovery, nausea 
and/or vomiting or requirements for postoperative analgesia. 
Saros G B
21
 et al did a study on desflurane versus sevoflurane as 
the main inhaled anesthetic for spontaneous breathing via a laryngeal 
mask airway for varicose vein day surgery. They concluded that 
desflurane is associated with a faster emergence with no differences 
during the postoperative course except a somewhat higher incidence of 
airway irritation. 
Wellborn LG
22
 et al compared the emergence and recovery 
characteristics of sevoflurane, desflurane, and halothane in paediatric 
ambulatory patients. They found that emergence and recovery from 
anesthesia were significantly faster in the desflurane group compared 
with the sevoflurane and halothane groups. There was a significantly 
greater incidence of postoperative agitation and excitement in patients 
who received desflurane versus sevoflurane and halothane. There were no 
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significant differences among the groups with respect to the time to meet 
home discharge criteria, in the time to drink oral fluids or in the incidence 
of postoperative vomiting. They concluded that , although desflurane 
resulted in the fastest early emergence from anesthesia, it was associated 
with a greater incidence of postoperative agitation. Sevoflurane resulted 
in similar emergence and recovery compared with halothane. 
Jalan Ergönenç
23
 et al in 2014 conducted a study on 40 ASA-PS 1 
and 2 patients posted for various general surgeries, and assessed 
postoperative recovery using modified Aldrete score (MAS), Mental and 
psychomotor functions of the patients were assessed using the short 
cognitive examination (SCE), and postoperative pain levels were assessed 
using the visual analogue scale (VAS). They concluded that time to 
recovery was shorter for Desflurane and also with better quality. The 
return of cognitive functions was also faster in the early postoperative 
period for Desflurane compared with Sevoflurane. Postoperative pain, 
blood pressure, heart rate and SpO2 values were affected similarly by 
both volatile agents.  
Marana
24
 et al conducted study on Fifty Caucasian women 
undergoing laparoscopic surgery for benign ovarian cysts comparing the 
effects of desflurane versus sevoflurane anesthesia on intra and 
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postoperative release of the stress hormones (noradrenaline, adrenaline, 
ACTH and cortisol) and inflammatory cytokines (IL-6 and CRP) by 
measuring their blood levels at predetermined regular intervals. They 
concluded that desflurane and sevoflurane produced a different stress 
response in the setting of laparoscopic surgery. Desflurane anesthesia led 
to greater release of adrenaline and noradrenaline, but not ACTH or 
cortisol, where as there was no significant change in sevoflurane group. 
The greater catecholamine releasing property of Desflurane may produce 
adverse effects in patients with pre-existing cardiovascular disease. The 
plasma levels of IL-6 and CRP were not influenced by both volatile 
anesthetics.
 
 
  
HISTORY OF
INHALATIONAL
ANESTHETICS
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HISTORY OF INHALATIONAL ANESTHETICS 
Inhalational anesthetics date back to the dawn of anesthesia. 
Humphry Davy first observed the analgesic effects of Nitrous oxide
4
 long 
ago in 1800, and called it as “laughing gas”. Horace Wells in 1844 
described the use of nitrous oxide to facilitate the extraction of a tooth.  
Henry Hill Hickman, in 1824 demonstrated that anesthesia could 
be induced and surgical procedures carried out using carbon dioxide.
4
 He 
was the one who introduced the concept of anesthesia using an inhaled 
substance. The first recorded general anesthetic administered in humans 
was in 1842, when both C W Long and W Clarke successfully induced 
anesthesia using diethyl ether.
4 
The first successful public demonstration of anesthesia was in 
1846, when W T G Morton successfully induced anesthesia using Ether 
on 16 October at Massachusetts General Hospital.
4 
Discovered in 1831, the use of chloroform in anesthesia is linked 
to James Young Simpson, who, in a wide-ranging study of organic 
compounds, found chloroform's efficacy on 4
th
 November 1847. 
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These two agents, along with nitrous oxide, remained the 
mainstays of anesthesia for the next 80 years, until the introduction of 
cyclopropane in 1930 by Lucas and Henderson in Toronto. Other agents 
used around this time included divinyl ether, trichloroethylene, and ethyl 
chloride. Lehmann first described the general anesthetic effects of 
trichloroethylene in 1911.
4 
In 1932, Booth and Bixby observed that the greatest potential for 
non-combustible anesthetic agents lay with organic fluoride compounds, 
because the substitution of fluoride for other halogens reduces the boiling 
point, increases the stability, and generally reduces the toxicity of gases.
4
 
Fluroxene, the first fluorine-containing anesthetic agent introduced in 
1950. 
First of the truly modern anesthetics, Halothane was first 
synthesised in 1951 by C W Suckling and was first introduced into 
clinical practice by Michael Johnstone in Manchester in 1956.
5
 Research 
into fluorinated compounds continued and has led to the production of all 
the modern anesthetic agents.  
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Methoxyflurane introduced in 1960, was soon withdrawn from the 
market due to its nephrotoxic potential. Fluroxene is explosive in 
concentrations greater than 3%. 
Enflurane was produced by R C Terrell of Ohio Medical Products 
and it was first used in man in 1966. It is a halogenated methyl ethyl 
ether. Isoflurane was first produced in 1968 by Dr R C Terrell. It is a 
structural isomer of enflurane, a halogenated methyl ethyl ether. 
Sevoflurane was first synthesised in the late 1960s at Baxter-
Travenol laboratories by R F Wallin and co-workers. The first recorded 
use in humans was in 1981.  
Desflurane was produced by Dr Ross Terrell and it was approved 
for clinical use in 1992. It is a fluorinated methyl ethyl ether.
 
Xenon, which is a noble gas, has gained wide interest recently 
about its anesthetic properties. It is a naturally occurring odourless 
nonexplosive gas , with good anesthetic and hemodynamic stability, but 
its costly distillation process and limited availability have prevented its 
widespread use.
5
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INHALATIONAL ANESTHETICS 
They are drugs administered by inhalation to provide general 
anaesthesia by their unique action and pharmacological properties. 
MECHANISM OF ACTION 
  Inhaled anesthetics act in different ways at the different levels in 
central nervous system. They act by disrupting the normal synaptic 
transmission by altering with the release of neurotransmitters from 
presynaptic nerve terminal (enhance or depress inhibitory or excitatory 
transmission respectively), by altering the binding of neurotransmitters to 
the post-synaptic receptor sites, by altering the re-uptake of 
neurotransmitters, and by influencing the ionic conductance change that 
follows activation of the post-synaptic receptor by neurotransmitters. 
Both, pre-synaptic and postsynaptic effects have been found. 
Direct interaction with the neuronal plasma membrane is very 
likely, but indirect action via production of a second messenger also has 
been hypothesized. There exists a high correlation between lipid 
solubility and anesthetic potency, which suggests that the inhalational 
anesthetics have a hydrophobic site of action. Inhalation agents bind to 
both membrane lipids and proteins. It was difficult at that point of time 
16 
 
that which of the different theories is most likely to be the main 
mechanism of action of volatile anesthetics. 
The affinity of anesthetic drugs for lipids was soon recognized, and 
this led to lipid-based hypothesis of anesthetic action. The formulation of 
the Meyer-Overton correlation
6,9
 at the end of the 19th century was a 
pioneering event, which introduced lot of anesthetic research into the 
volatile anesthetics. Meyer concluded in 1899 that “All chemically 
indifferent substances that are soluble in fat are anesthetics. Their relative 
potency as anesthetics will depend on their affinity to fat on the one hand 
and water on the other hand, that is, on the fat/water partition 
coefficient,” a conclusion that was also reached independently by 
Overton. 
The Meyer-Overton theory describes the correlation between the 
lipid solubility of inhalational anesthetics and Minimum Alveolar 
Concentration. They suggested that anesthesia occurs when a sufficient 
number of inhalational anesthetic molecules dissolve in the lipid cell 
membrane. The Meyer-Overton rule postulates that the number of 
molecules dissolved in the lipid cell membrane and not the type of 
inhalation agent causes anesthesia. There may be additive effects at the 
17 
 
level of the cell membrane if combinations of different inhaled 
anesthetics are used. 
However, why anesthesia occurs is not explained by the Meyer-
Overton theory. Mullins redefined the Meyer-Overton theory by adding 
the hypothesis -called Critical Volume Hypothesis. They stated that the 
absorbed anesthetic molecules could expand the volume of a hydrophobic 
region within the cell membrane and thereby distort channels required for 
sodium ion influx and the development of action potentials necessary for 
synaptic transmission. Later on, it was proved that anesthesia occurs with 
significant increase in volume of hydrophobic solvents and is reversible 
by compressing the volume of the expanded hydrophobic region of the 
cell membrane , which supports Mullins Critical Volume Hypothesis. 
A focus on protein targets gained momentum in the 1980s owing 
largely to the work of Franks and Lieb, who demonstrated that protein 
targets are also compatible with the Meyer-Overton correlation and 
proposed that anesthetics competitively antagonize protein function. The 
enantiomeric selectivity of several anesthetics further strengthened the 
case for specific binding sites on proteins, such as ion channels, as the 
principal molecular targets of inhaled anesthetics. Today, there is 
widespread (but not universal) acceptance of the notion that critical 
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signalling proteins (e.g., ion channels and receptors) are the relevant 
molecular targets of anesthetic action even though the mechanisms of 
their modulation by anesthetics are debated. 
MOLECULAR TARGETS OF INHALED ANESTHETICS 
Recently, ion channels have been studied as the most promising 
molecular targets for volatile anesthetics. Neurotransmitter-gated ion 
channels, in particular GABAA, glycine, and NMDA-type glutamate 
receptors, are leading targets owing to their appropriate CNS 
distributions, important physiologic roles in inhibitory and excitatory 
synaptic transmission, and sensitiveness to clinically relevant 
concentrations of anesthetics.
6
 Other ion channels that are sensitive to 
inhaled anesthetics include the HCN (hyperpolarization-activated cyclic 
nucleotide-gated) family of channels that give rise to pacemaker currents
 
and regulate dendritic excitability, two-pore domain (K2P) “leak” K
+
 
channels that maintain resting membrane potential in many cells, and 
voltage-gated Na
+
 and Ca
2+
 channels.
6 
Inhaled anesthetics can be broadly divided into two classes based 
on their pharmacologic properties. The first class is the potent inhaled 
(volatile) anesthetics, which exhibit positive modulation of GABAA 
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receptors, enhancement of inhibitory glycine receptors, inhibition of 
excitatory NMDA and neuronal nicotinic acetylcholine receptors, 
activation of K2P channels, and inhibition of presynaptic Na
+
 channels. 
The second class is the gaseous inhaled anesthetics, which include 
cyclopropane, nitrous oxide, and xenon. These anesthetics are inactive at 
GABAA receptors, but block NMDA receptors and activate certain K2P 
channels at clinical concentrations.  
 MINIMUM ALVEOLAR CONCENTRATION (MAC) 
The potency of volatile anesthetics is measured by the minimum 
alveolar concentration (MAC). This value represents the minimum 
percent alveolar concentration of an anesthetic (at one atmosphere) that 
prevents movement in 50 percent of the subjects in response to a 
supramaximal stimulus, mostly surgical skin incision. In daily practice, to 
achieve immobility in 95 percent of subjects, MAC must be exceeded by 
a factor of 1.3, as 1 MAC alone denotes ED50. The idea of measuring 
MAC is that after a short period of equilibration, the alveolar 
concentration of the inhalational anesthetic equals the blood 
concentration and a little later equals the brain concentration. As per 
Dalton’s law of partial pressure of gases, partial pressure can be 
substituted for concentration. Therefore , it represents after a short time 
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the partial pressure of the anesthetic in the central nervous system (CNS) 
and it is therefore the most useful index of anesthetic potency. 
MAC is age-dependent, being lowest in newborns, reaching a peak 
in infants, and then decreasing progressively with increasing age.
8
 MAC 
values for inhaled anesthetics are additive, which means that the addition 
of nitrous oxide will decrease the MAC of another volatile anesthetic. 
The MAC can also be reduced following administration of opioids. 
Increases in MAC result from hyperthermia and hypernatremia. 
Decreases in MAC can result from hypothermia, hyponatremia, 
pregnancy, hypotension, and drugs such as lithium, lidocaine, opioids, 
and α2 agonists. 
MAC provides a unifying principle of assessing anesthetic depth 
for the inhaled anesthetics. Although each inhaled anesthetic has some 
pharmacologic peculiarities, in general they have parallel dose-response 
curves across drugs (e.g., isoflurane versus sevoflurane versus 
desflurane). 
MAC- it is the end-tidal concentration of the inhaled anesthetic at 
one atmospheric pressure required to prevent movement in response to a 
noxious stimulus in 50% of subjects. ( example - MAC of nitrous oxide- 
104%, sevoflurane- 1.8 to 2 % ). 
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MAC AWAKE- it is the end-tidal concentration associated with 
response to verbal stimulation in 50% of subjects. It is usually 0.3 – 0.4 
MAC 
MAC INTUBATION- the end-tidal concentration of the inhaled 
anesthetic that would inhibit movement and coughing during 
endotracheal intubation. It is usually 1.3 MAC 
MAC BAR- the end-tidal concentration of the inhaled anesthetic 
that blocks adrenergic response in 50% of subjects. It is usually 1.5 
MAC.
7 
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UPTAKE AND DISTRIBUTION OF INHALED ANESTHETICS 
A series of partial pressure gradients exists, which beginning at the 
vaporizer of the anesthetic machine, continuing in the anesthetic 
breathing circuit, the alveolar tree, blood, and tissue.
10
 The forward 
movement of the gases is ensured by this pressure gradient and it will 
continue to happen till they achieve equal partial pressures on both sides 
of each single barrier. The partial pressure of the anesthetic in various 
body tissues is governed by the alveolar partial pressure ; and 
eventually the partial pressure in all compartments will tend to be equal to 
that of alveoli. After a short period of equilibration, the alveolar partial 
pressure of the gas equals the brain partial pressure.
10 
At equilibrium,  
P.Alveoli = P.Blood = P.Brain 
It is thus important to know about the factors which influence the alveolar 
partial pressure. It can be raised by increasing minute ventilation, setting 
the vaporizer dial to a higher concentration and by using a non-
rebreathing circuit.  
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The concentration effect 
  Describes how the concentration of the gas in the remaining 
alveolar volume can increase after some of the gas has been transferred 
into the blood.  
The second gas effect 
Usually refers to nitrous oxide combined with an inhalation agent. 
Because nitrous oxide is not soluble in blood, its rapid absorption from 
alveoli causes an abrupt rise in the alveolar concentration of the other 
inhaled anesthetic. 
All the above mentioned factors influence the inflow of gas into the 
alveoli. Solubility, cardiac output, and the alveolar to arterial anesthetic 
gradient represent outflow factors. Inflow factors minus outflow factors 
corresponds to alveolar partial pressure of the gas. 
Solubility 
It describes the affinity of the gas for a medium such as blood or 
fat. The blood/gas partition coefficient describes how the gas will 
partition itself between the two phases after equilibrium has been 
reached. Sevoflurane for example has a blood/gas partition coefficient of 
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0.65. This means that if the gas is in equilibrium, the concentration in 
blood will be 0.65 times the the concentration in the alveoli. 
 A higher blood gas partition coefficient means  
- A higher uptake of the gas into the blood  
- Slower induction time. 
-  Takes longer time till equilibrium with the brain partial 
pressure of the gas is attained. 
Cardiac Output 
A higher cardiac output removes more volatile anesthetic from the 
alveoli and therefore lowers the alveolar partial pressure of the gas. The 
agent might be faster distributed within the body but the partial pressure 
in the arterial blood is lower. It will take longer for the gas to reach an 
equilibrium between the alveoli and the brain. Therefore, a high cardiac 
output prolongs induction time. This is especially significant with more 
soluble agents. 
Alveolar to arterial partial pressure difference 
The alveolar to arterial partial pressure difference also determines 
tissue uptake of the inhaled anesthetic. A large difference is caused by 
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increased uptake of the gas during the induction phase. This facilitates the 
diffusion of the gas from the alveoli into the blood. 
The transfer of the gas from the arterial blood into the tissues 
depend on perfusion and solubility of the gas into different tissues. The 
brain/blood coefficient describes how the gas will partition itself between 
brain and blood after attaining equilibrium. Sevoflurane for example has 
a brain/blood coefficient of 1.7 meaning that if the gas is in equilibrium, 
the concentration in the brain will be 1.7 times higher than the 
concentration in the blood. All inhalation anesthetics have high fat/blood 
partition coefficients. This means that most of the gas will dissolve in 
fatty tissue as time goes on and the partial pressure of the gas in fatty 
tissue will rise very slowly. Inhalation anesthetics stored in such tissue in 
obese patients may delay recovery. The body tissues have been divided 
into groups according to the level of perfusion and blood flow. 
 Vessel rich group  (VRG)  -  brain, heart, kidney, liver 
 Muscle group (MG)   -  muscle and skin 
 Fat group (FG)    -  large capacity / minimal  
      flow 
 Vessel poor group (VPG)  -   bone, cartilage and  
      connective tissue 
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Tissue Group Characteristics 
  
Group 
Vessel 
Rich 
Muscle Fat 
Vessel 
Poor 
Percentage of body mass 10 50 20 20 
Perfusion as a percentage of cardiac 
output 
75 19 6 0 
 
Metabolism and elimination of inhaled anesthetics 
  Metabolism is important for two reasons. First, metabolites or 
breakdown products from exposure to carbon dioxide absorbents may be 
toxic to the kidneys, liver, or reproductive organs. Second, the degree of 
metabolism may influence the rate of decrease in the alveolar partial 
pressure.  
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Assessment of the magnitude of metabolism of the inhaled 
anesthetics is by 
(a)  Measurement of metabolites or 
(b)  Comparison of the total volume of anesthetic recovered in the 
exhaled gases with the amount administered. (Mass balance). 
Determinants of metabolism 
The magnitude of metabolism of inhaled anesthetics is determined by the  
-  Chemical structure 
-  Hepatic enzyme activity 
-  Blood concentration of the anesthetic 
-  Genetic factors 
Chemical Structure- the ether bond and carbon-halogen bond are the 
most susceptible sites in the anesthetic molecule for oxidative 
metabolism. 
Hepatic Enzyme Activity- the activity of hepatic cytochrome P-450 
enzymes responsible for metabolism of volatile anesthetics may be 
increased by a variety of drugs, including the anesthetics itself.  
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Blood Concentration- the fraction of anesthetic that is metabolised on 
passing through the liver is influenced by the blood concentration of the 
anesthetic. Inhaled anesthetics that are not highly soluble in blood and 
tissues tend to be exhaled rapidly via the lungs. As a result, less drug will 
only be available to pass through the liver at low blood concentrations.  
Genetic factors- overall, genetic factors appear to be the most important 
determinant of drug-metabolising enzyme activity. In this regard, humans 
are active metabolizers of drugs compared to lower animal species such 
as the rat. 
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PHARMACOLOGY OF DESFLURANE 
 
Desflurane was produced by Dr Ross Terrell. It was approved for 
clinical use in 1992. 
Physical properties 
 Desflurane is a fluorinated methyl ethyl ether. 
 Has a pungent odour, irritating and unpleasant to inhale. 
 Molecular weight: 168.04 Dalton  
 Boiling point: 22.8 ºC 
 Saturated vapour pressure: 664 mmHg 
 Blood-gas solubility: 0.42 
 Minimum alveolar concentration: 6% 
Chemical structure 
 
2,2,2-trifluoro-1-fluoroethyl-difluoromethyl ether 
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Pharmacokinetics 
Desflurane has the lowest blood-gas solubility of all the volatile 
anesthetics. Thus, it results in faster induction and faster recovery. At 30 
mins, after starting volatile anesthetic, the FA/FI ratio of desflurane was 
0.9 compared to 0.73 for isoflurane and 0.58 for halothane. 
Partition Coefficients of desflurane at 37ºC: 
Blood-Gas   :  0.42 
Brain-blood  :  1.3 
Liver-Blood  :  1.4 
Kidney-Blood  :  1.0 
Muscle-Blood  :  2.0 
Fat-Blood   :  27 
The distribution of desflurane follows a five-compartment model 
which, it has been postulated, may be as follows – the lungs, the vessel-
rich group of organs, muscle, fat around the vessel rich organs, and 
finally, peripheral fat. 
The elimination of desflurane is almost exclusively through the 
lungs, with metabolism by the liver estimated to be less than 0.02%. 
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Pharmacodynamics 
Central nervous system 
Cerebral blood flow- Desflurane has two effects on cerebral blood 
flow. Cerebral vasodilatation causes increase in cerebral blood flow while 
decrease in cerebral metabolic rate causes decrease in cerebral blood 
flow. Of these, vasodilatation predominates and there is global increase in 
cerebral blood flow. 
Cerebral metabolic rate- Desflurane causes a reduction in cerebral 
metabolic rate. 
Intracranial pressure- drug induced vasodilatation tends to raise 
the intracranial pressure. This effect is not offset by hypocapnia. 
The more rapid recovery associated with desflurane anesthesia may 
offer a small advantage in patients undergoing prolonged neurosurgical 
procedures. 
Respiratory system 
Desflurane is irritating to the airway. So, it is not suitable for 
inhalation induction. Concentrations of desflurane more than 6% cause 
coughing, breath-holding, and laryngospasm both in adults and children. 
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It is a potent respiratory depressant. It causes a dose-dependent 
decrease in tidal volume and an increase in respiratory rate, with an 
overall reduction in minute alveolar ventilation. Paco2 increases and the 
ventilatory response to carbon dioxide is reduced. 
Cardiovascular system 
Desflurane causes peripheral vasodilatation, which results in dose-
dependent tachycardia associated with direct depression of myocardial 
contractility and a decrease in systemic vascular resistance. These 
changes occur at concentrations ranging from 0.83 to 1.66 MAC. 
It is a direct coronary vasodilator and produces an overall reduction 
in cardiac work. A rapid increase in the concentration of desflurane to 
greater than 1 MAC will cause an increase in heart rate and blood 
pressure.  
Desflurane does not sensitize the myocardium to epinephrine. 
Neuromuscular effects 
Desflurane depresses neuromuscular function. It also potentiates 
the action of nondepolarizing muscle relaxants. It can provide sufficient 
relaxation to allow tracheal intubation.  
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Toxicity  
Desflurane has low blood-gas and blood-tissue solubility and 
undergoes minimal metabolism less than 0.02 % by liver. Trifluoroacetic 
acid, which is a metabolite, may interact with hepatic proteins and induce 
an immune response in susceptible patients.  
There is no evidence of renal toxicity, even after prolonged 
exposure. 
Desflurane, under certain conditions is degraded by carbon dioxide 
absorbers, and carbon monoxide is produced. 
Desflurane is a trigger agent for malignant hyperthermia. 
Clinical uses 
Desflurane has low blood-gas solubility and therefore provides 
most rapid induction and recovery. It undergoes minimal metabolism and 
the risk of toxicity is very low. As Desflurane boils at room temperature 
(boiling point – 22.8 ºC ), it requires a special vaporizer with built-in 
heater for continuous supply of vapour. 
 
PHARMACOLOGY
OF
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PHARMACOLOGY OF SEVOFLURANE 
Sevoflurane was first synthesized in the late 1960s at Baxter-
Travenol laboratories by R F Wallin and co-workers. The first published 
recorded use in humans was in 1981. 
Physical properties 
 Sevoflurane is a fluorinated methyl isopropyl ether. 
 It is colourless, non pungent to inhale, non-flammable and a liquid 
at room temperature. 
 Molecular weight: 200.5 Dalton  
 Boiling point: 58.5 ºC 
 Saturated vapour pressure: 160 mmHg 
 Blood-gas solubility: 0.69 
 Minimum alveolar concentration: 2% 
Chemical structure  
 
1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)propane 
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Pharmacokinetics 
Sevoflurane has a low blood-gas partition coefficient which means 
that it has a rapid induction and rapid recovery. At 30 minutes after the 
start of anesthesia, the FA/FI (fraction of alveolar to the inspired 
concentration) for sevoflurane was 0.85 compared with 0.73 for 
isoflurane.  
Partition Coefficients of sevoflurane at 37ºC 
Blood-Gas   :  0.69 
Brain-blood  :  1.7 
Liver-Blood  :  1.8 
Kidney-Blood  :  1.2 
Muscle-Blood  :  3.1 
Fat-Blood   :  48 
The distribution of sevoflurane follows a five compartment model. 
Elimination of sevoflurane is primarily through the lungs and only 
a smaller amount is metabolised. The proportion metabolised has been 
estimated at between 1.6 % and 4.9%. Metabolism occurs in the liver, 
catalyzed by the cytochrome P450E1 enzyme. 
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Pharmacodynamics 
Central nervous system 
Cerebral blood flow: Sevoflurane causes cerebral vasodilatation 
and decrease in cerebral metabolic rate. Of these, vasodilatation 
predominates with a global increase in cerebral blood flow. 
Cerebral metabolic rate: There is a reduction in cerebral metabolic 
rate. 
Intracranial pressure: Sevoflurane causes a slight rise in the 
intracranial pressure. There is some evidence that sevoflurane has 
neuroexcitatory properties. 
The cerebrovascular response to carbon dioxide and 
cerebrovascular autoregulation are both impaired under sevoflurane 
anaesthesia when MAC is >1.5 . 
Respiratory system 
Sevoflurane is pleasant to inhale and virtually has no irritant effect 
on the airway. This, combined with its low blood-gas solubility makes it 
suitable for inhalational induction. It is a respiratory depressant, causing a 
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reduction in minute ventilation. Tidal volume is reduced and respiratory 
rate is increased.. The ventilatory response to carbon dioxide is reduced. 
Sevoflurane abolishes hypoxic pulmonary vasoconstriction in a 
dose-dependent manner. Sevoflurane is an effective bronchodilator. 
Cardiovascular system 
Sevoflurane can produce direct myocardial depression through an 
action on calcium channels. It causes a dose dependent reduction in 
cardiac output and a reduction in systemic vascular resistance which 
results in a fall in systemic blood pressure. Sevoflurane does not have 
significant effect on heart rate at 1 MAC. 
It causes a reduction in pulmonary artery pressure that is not dose 
dependent. 
Hepatic and renal blood flows are preserved. 
Sevoflurane does not sensitize the myocardium to epinephrine. It is 
a coronary vasodilator. It does not cause the sympathetic-mediated 
cardiovascular stimulation associated with rapid increases in end-tidal 
concentration. 
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Neuromuscular effects 
Sevoflurane produces dose dependent muscle relaxation. At deeper 
levels of anesthesia, it facilitates tracheal intubation. 
It potentiates the action of neuromuscular blocking agents. 
Toxicity 
Metabolism is less significant because its tissue solubility is so 
low. Metabolism of sevoflurane results in production of inorganic 
fluoride and hexafluoroisopropanol. When sevoflurane is exposed to 
soda-lime or baralyme, it is absorbed and degraded to a variety of 
compounds of which two are produced in significant amounts. They are 
fluoromethyl-2, 2-difluoro-1-(trifluoromethyl) vinyl ether (Compound A)
11
 and 
fluoromethyl-2-methoxy-2,2-difluoro-1-(trifluoromethyl) ethyl ether 
(Compound B ). 
Toxic level of fluoride to produce nephrotoxicity is greater than 
80µmol/litre. The lower the flow rate in the circle system, the higher will 
be the concentration of Compound A. The addition of water to soda-lime 
and the use of partially exhausted soda-lime increases the chance for 
production of Compound A during low-flow anesthesia. While there is no 
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evidence to date of serious long-term renal injury associated with the use 
of sevoflurane, it would seem prudent to avoid prolonged exposure to 
sevoflurane with fresh gas flows of less than 2L/min. 
Sevoflurane is not hepatotoxic. Sevoflurane triggers malignant 
hyperthermia. 
Clinical use 
Sevoflurane has a low blood-gas solubility, so faster induction and 
faster recovery which along with its pleasant odour, makes it an ideal 
agent for inhalational induction. Toxicity has not been proved to be a 
clinical problem even with low flows for prolonged periods.  
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THYROID SURGERY 
Thyroidectomy is the most common endocrine surgical procedure 
being carried out throughout the world. The anaesthetist often faces 
certain challenges while dealing with thyroidectomy cases, which can 
mark its appearance anytime, be it in pre-op , intra-op or post-op period. 
The deranged endocrine homeostasis that might be unrecognized, 
especially while handling the thyroid gland during surgery can produce 
stimulation of sympathetic responses. So, maintaining a good 
hemodynamic stability becomes a high priority for the anaesthetist. 
In the pre-operative setting, the primary goal of the anaesthetist 
while dealing with elective thyroidectomy surgeries is to make sure that 
the patient is euthyroid. Pre-operative optimization of thyroid hormone 
levels is a must before taking up elective thyroid surgery. Poorly prepared 
cases might cause catastrophic complication like thyroid storm. The 
possibility of facing a difficult airway should always be borne in mind, 
especially in large thyroid swellings, those with retrosternal extension and 
also long standing thyroid swelling.  
Intraoperatively, the thyroid surgery may extend from simple 
excision of the thyroid nodule, to hemithyroidectomy or subtotal 
thyroidectomy or even total thyroidectomy. The potential risk of 
uncontrolled haemorrhage will be there, be it from major vessels in 
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vicinity of thyroid gland or from the thyroid vessels itself. Any sudden 
rise in blood pressure can worsen the haemorrhage. Hypothyroidism, if 
not corrected before taking up for surgery, can pose certain problems , 
like depressed myocardial function, altered baroreceptor function, 
reduced ventilatory drive, hypoglycaemia and reduced hepatic 
metabolism. 
Though propylthiouracil and methimazole have been used 
extensively, carbimazole is the drug of choice in preparing a hyperthyroid 
patient for the elective surgery.
2
 The increased vascularity of thyroid 
gland by carbimazole, however, exposes the patient to potential risks of 
higher bleeding during the surgical procedure. Also, decreased WBC 
count as a result of carbimazole therapy makes the patient vulnerable to 
numerous infections during post-op period 
If the patient was in hyperthyroid status, to become euthyroid, the 
patient has to started on Carbimazole or Propylthiouracil. But starting on 
Carbimazole, which is the widely used antithyroid drug, can cause 
increased vascularity of thyroid gland and can predispose for more 
intraoperative bleeding.
2
  
Maintenance of Anesthesia during thyroidectomy deals with 
making the patient unaware of the severe stimulation and also by 
providing excellent analgesia and immobility. Maintenance of anesthesia 
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can be provided by inhalational anesthetics such as sevoflurane or 
desflurane in nitrous oxide anesthesia. The blunting of the stimulation 
and awareness is made possible by the volatile anesthetics . Also it 
potentiates the action of neuromuscular blocking agents there by reducing 
the dose required for providing immobility. The inhalation agents have an 
inhibitory effect on the sympathetic nervous system, which is especially 
important for patients with hyperthyroidism 
Patients with established hypothyroidism have decreased metabolic 
rate and a decreased capacity to metabolize the drugs which can prolong 
the recovery from the effects of anesthetic agents. 
The prevention of stress response during extubation is widely 
appreciable as it can avoid any accidental hemorrhage from the wound 
site due to bucking movements from the trachea during reversal of 
anesthetic and muscle relaxant effects.  
Postoperatively, numerous complications can develop that include 
hemorrhage, laryngeal edema, nerve palsies, tracheomalacia, 
hypocalcemic tetany etc.  
MATERIALS
AND
METHODS
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MATERIALS AND METHODS 
After institutional ethical committee approval, the study was 
conducted in 70 patients. All were ASA I and II patients undergoing 
elective Thyroidectomy under general anesthesia lasting for less than 2 
hours duration. After getting informed consent, general anesthesia was 
given using either Desflurane or Sevoflurane and study conducted. 
Duration of the Study 
 June 2016 – May 2017  
Sample Size 
Sample size was calculated based on Master 2.0 software with 
alpha error of 5% and power of 80%. Sample size was found to be 35 per 
group. 
SELECTION OF PATIENTS 
The patients selected for this study were of ASA Physical Status 
grade I&II undergoing elective thyroidectomy under general anesthesia 
lasting for less than 2 hours duration. It was a prospective randomized 
control study. 
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Inclusion criteria 
 18 – 60 yr old of either sex 
 Weight 50 – 90 kg 
 Height 150 – 180 cm 
 ASA I-II patients scheduled for elective thyroid surgeries of more 
than one hour duration and less than two hours duration under 
general anesthesia 
Exclusion criteria 
 Patient unwilling 
 Belonging to ASA 3 or 4 
 History of psychiatric disorder 
 Pregnancy 
 Chronic alcoholism 
 Has undergone recent GA within 7 days 
 Patients chronically receiving opioid analgesics or sedative 
medication 
 History of allergy to drugs 
 Potential susceptibility to malignant hyperthermia. 
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PREOPERATIVE PREPARATION 
In the preoperative examination, all the patients were asked for 
history of systemic illness like hypertension, diabetes, seizure disorder, 
bronchial asthma. History of muscular dystrophies, neuromuscular 
disorders and family history of malignant hyperthermia were noted. 
History of any allergic reactions to drugs and chronic drug intake were 
noted. History of any previous surgeries was noted. Examination of the 
cardiovascular system and respiratory system were done. Assessment of 
the airway and the range of neck movements were done to rule out 
possibilities for difficult intubation. Thus patients satisfying the inclusion 
criteria were investigated for 
 Haematological (Hb%, TC,DC,PLT count) 
 Pre-operative biochemical(RFT &LFT) and blood sugar profile  
 Thyroid Function Test  
 Chest Xray PA view & Neck Xray AP-Lateral view  
 12 lead ECG 
 Indirect laryngoscopy  
Hypertensive patients were advised to continue the 
antihypertensives on the day of surgery. Diabetic patients were advised to 
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skip the morning dose of insulin or oral hypoglycemic agents. The 
surgeons were instructed to post the diabetic case first in the list and to 
send the patient to the operating room with the fasting blood sugar, serum 
electrolytes and urine acetone values taken on the day of surgery. 
On arrival to the preoperative room, informed consent was 
obtained for the participation of the patient in the study and PARS score 
(Post Anesthetic Recovery Score of Aldrete and Kroulik) and methods of 
recovery assessment were explained to the patient. 
The patients were randomly allocated into two groups by slips in 
box technique: 
 GROUP S - Sevoflurane 35 patients 
 GROUP D -Desflurane 35 patients 
  Patient shifted to the operation theatre by a trained personnel on a 
trolley. 
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PROCEDURE DETAILS 
 WHO CHECKLIST gone through 
 In operation theatre, Standard monitors-Pulse oximetry for 
saturation (SpO2), Noninvasive blood pressure monitoring (NIBP), 
Electrocardiogram (ECG) were connected and baseline pulse rate, 
mean arterial pressure, oxygen saturation were recorded. 
Intravenous line access obtained with 18 G cannula and crystalloid 
infusion started. Airway cart and rescue measures kept ready. 
 Premedication : injection Midazolam 0.05mg/kg, injection 
Glycopyrrolate 10µg/kg intravenously and injection Fentanyl 
2µg/kg IV 
 Preoxygenation with 100% oxygen for 3 minutes 
 
Induction : Inj Propofol 2mg/kg IV, and muscle relaxant, with  
Inj Vecuronium 0.1mg/kg IV 
 
Intubated with 7- 7.5 size ETT or 8 – 8.5 size ETT for women and 
men respectively , after direct laryngoscopy 
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 Group S was maintained with 2% sevoflurane and group D with 
6% desflurane in 33% oxygen with 67% nitrous oxide 
 Ventilation was controlled to maintain end-tidal carbon dioxide 
between 32and 36mmhg, with tidal volume 6-8 ml/kg and RR 
10-12/min. 
 Injection fentanyl 0.5µg/kg was repeated every 30 minutes. 
 Injection vecuronium 0.02mg/kg was repeated every 30 minutes 
 Mean arterial pressure and heart rate were noted before 
induction and every 5minutes after induction, including post-
intubation and post-extubation. 
 The maintenance dose of anesthetics were titrated to maintain a 
PRST score
12
 </= 3. 
 If there was any increase in the mean arterial pressure and heart 
rate more than 20% of the preinduction values, an additional 
dose of injection Fentanyl 1µg/kg would be given to maintain 
the hemodynamics. 
 If there was any reduction in the mean arterial pressure more 
than 20% from the baseline value, it would be treated with  
100 ml bolus of isotonic intravenous fluids and replacement of 
intraoperative blood loss. 
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 When the hemodynamics of the patient were unresponsive to 
the above measures, the patient was excluded from the study 
and vitals optimized accordingly. 
 Nitrous oxide and volatile anesthetic discontinued after the last 
skin suture. 
 
 After discontinuation of the volatile agent, a blinded 
investigator was posted for extubation and for assessing the 
recovery of the patient from general anesthesia. 
 Residual neuromuscular blockade reversed with injection 
neostigmine 40µg/kg and injection glycopyrrolate 10µg/kg 
intravenously. 
 Trachea  extubated when regular spontaneous breathing pattern 
re-established and when the patients were able to open their 
eyes on command. 
 The time of discontinuation of anesthetic agents was noted as 
time zero for all the subsequent measurements and recovery 
time determined at 1-minute intervals to awakening. 
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PARAMETERS OBSERVED: 
 Number of additional doses of fentanyl needed. 
 TIME TO-   
1.  First spontaneous motion 
 2.  Response to painful pinch 
 3.  Extubation 
 4.  Recall of name 
 5.  Hand grip  
 6.  Achieve PARS ≥ 10 (post anesthesia recovery score of  
Aldrete and Kroulik) 
This PARS
13
 records vital signs with patients receiving 0-11 points. 
One designated investigator administered all anaesthesia and another 
assessed recovery. 
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POST ANESTHESIA RECOVERY SCORE OF   
ALDRETE AND KROULIK 
 
Consciousness 
Easily arousable, alert     3 
Arousable, oriented, not alert    2 
Arousable, not oriented     1 
Not responding      0 
Ventilation 
Normal       2 
Not perfect, but requires no support   1 
Airway requires support     0 
Circulation (mean, supine, sitting) 
Arterial pressure difference 
< 10 %       2 
10-20        1  
>20 %       0 
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Horizontal nystagmus 
Follow command, no nystagmus   2 
Follow command, nystagmus    1 
 Fail to follow command     0 
Countdown test ( backward from 10 to 0 ) 
Succeed right away     2 
Succeed in 30 seconds     1 
Fail in 30 seconds      0 
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OBSERVATION AND RESULTS 
AGE DISTRIBUTION 
CHART-1 
 
TABLE -1 
Age Group 
GROUP-D GROUP-S 
No. % No. % 
≤ 25 4 11.43 1 2.86 
26 - 35 10 28.57 13 37.14 
36 - 45 10 28.57 11 31.42 
46 - 55 8 22.86 5 14.29 
≥56 3 8.57 5 14.29 
TOTAL 35 100 35 100 
Mean ± SD 38.91 ± 10.72 40.09 ± 10.23 
t-value 0.47 
df 68 
p-value 0.64 (Not Significant) 
 
Cases studied in the desflurane group had an age of 38.91 +10.72 
years and the sevoflurane group had an age of 40.09+ 10.23 years. There 
was no statistically significant difference 
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MEAN AGE 
TABLE-2 
Age 
GROUP-D GROUP-S 
MEAN SD MEAN SD 
MALE 41.58 9.68 42.00 11.98 
FEMALE 37.52 11.17 39.52 9.84 
TOTAL 38.91 10.72 40.09 10.23 
 
The mean age of the patients was comparable in both the groups. 
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GENDER DISTRIBUTION 
CHART-2 
 
TABLE-3 
 GROUP-D GROUP-S TOTAL 
NO. % NO % NO. % 
MALE 12 34.29 12 34.29 24 34.29 
FEMALE 23 65.71 23 65.71 46 65.71 
TOTAL 35 100 35 100 70 100 
SEX RATIO 
(Male: Female) 
12 : 23 12 : 23 20 : 50 
 
The sex ratio of the two groups was identical without any 
difference. 
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WEIGHT 
CHART-3 
 
TABLE-4 
GROUP-D GROUP-S 
t-value Df p-value 
MEAN 
(Kg) 
SD 
MEAN 
(Kg) 
SD 
60.14 4.70 61.60 5.05 1.25 68 0.22* 
 
The weight of the patients was comparable in both the groups. 
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DIAGNOSIS 
CHART-4 
 
TABLE - 5 
 GROUP-D GROUP-S 
NO. % NO. % 
LEFT COLLOID GOITRE 12 34.29 9 25.72 
MULTINODULAR GOITRE 12 34.29 10 28.57 
PAPILLARY CARCINOMA 0 0 3 8.57 
RIGHT COLLOID GOITRE 11 31.42 13 37.14 
TOTAL 35 100 35 100 
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SURGERY  
TABLE - 6 
 GROUP-D GROUP-S 
NO. % NO. % 
HEMITHYROIDECTOMY 23 65.71 22 62.86 
SUBTOTAL THYROIDECTOMY 12 34.29 13 37.14 
TOTAL 35 100 35 100 
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ASA - PHYSICAL STATUS 
CHART-5 
 
TABLE-7 
ASA-PS 
GROUP-D GROUP-S 
NO. % NO. % 
1 22 62.86 18 51.43 
2 13 37.14 17 48.57 
TOTAL 35 100 35 100 
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HEART RATE 
CHART-6 
 
 
 Baseline and intraoperative heart rate were comparable between 
the desflurane and sevoflurane groups. There was no statistically 
significant difference. 
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TABLE-8 
TIME 
(MINUTE) 
GROUP-D GROUP-S 
t-
value 
df 
p-
value 
MEAN SD MEAN SD 
BASELINE 82.57 6.12 83.83 7.82 0.75 68 0.46* 
INDUCTION 75.31 7.14 75.11 7.44 0.12 68 0.91* 
5(POST-
INTUBATION) 
82.00 6.97 82.37 8.04 0.21 68 0.84* 
10 80.06 6.83 79.60 8.96 0.24 68 0.81* 
15 78.97 6.88 78.11 8.74 0.46 68 0.65* 
20 77.11 5.75 77.43 8.41 0.18 68 0.86* 
25 76.54 5.52 76.71 8.37 0.10 68 0.92* 
30 76.66 5.26 76.00 8.88 0.38 68 0.71* 
45 75.80 5.78 74.66 8.40 0.66 68 0.51* 
60 77.63 7.23 76.94 8.83 0.36 68 0.72* 
75 75.97 6.32 74.49 7.15 0.92 68 0.36* 
90 77.60 7.47 76.03 7.02 0.91 68 0.37* 
105 84.03 7.42 80.89 7.49 1.76 68 0.08* 
110 85.30 8.32 85.26 7.85 0.02 52 0.98* 
115 87.94 6.03 89.10 7.26 0.52 35 0.61* 
120 93.83 4.97 95.43 6.90 0.67 24 0.51* 
* Not Significant 
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COMPARISON OF PERCENTAGE DIFFERENCE BETWEEN 
INTRAOPERATIVE HEART RATE AND BASELINE HEART 
RATE 
CHART-7 
 
The mean heart rate of Desflurane group as well as of Sevoflurane 
group noted at induction, at 5 (post intubation) and 10 minutes, and post 
extubation all lie within 20 percent range from mean baseline heart rate. 
The percentage difference at each stage compared to baseline in both 
groups were similar. 
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TABLE-9 
 
DESFLURANE SEVOFLURANE 
Time Mean SD 
Mean 
difference 
from 
baseline 
Percentage 
difference 
from 
baseline 
Mean SD 
Mean 
difference 
from 
baseline 
Percentage 
difference 
from 
baseline 
Baseline 82.57 6.12 - - 83.83 7.82 - - 
Induction 75.31 7.14 -7.26 8.79 75.11 7.44 -8.72 10.4 
5 minutes 
(Post-
Intubation) 
82 6.97 -0.57 0.69 82.37 8.04 -1.46 1.74 
10 minutes 80.06 6.83 -2.51 3.04 79.6 8.96 -4.23 5.05 
Post 
extubation 
92.86 4.39 10.29 12.46 93.86 5.96 10.03 11.96 
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MEAN ARTERIAL PRESSURE 
CHART-8 
 
The baseline and intraoperative mean arterial pressure in both 
desflurane and sevoflurane groups were comparable with no statistically 
significant difference. 
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TABLE-10 
TIME 
(MINT) 
GROUP-D GROUP-S t-
value 
Df 
p-
value MEAN SD MEAN SD 
BASE 90.14 6.92 91.91 6.25 1.12 68 0.27* 
INDUCTION 81.49 8.22 82.49 7.80 0.52 68 0.60* 
5(POST-
INTUBATION) 
85.83 8.13 87.23 8.49 0.70 68 0.48* 
10 83.94 7.44 85.29 7.72 0.74 68 0.46* 
15 83.06 7.29 83.71 7.80 0.36 68 0.72* 
20 82.89 7.14 82.74 7.70 0.81 68 0.94* 
25 82.51 7.01 82.51 7.44 0.01 68 1.00* 
30 82.23 6.91 82.17 7.10 0.34 68 0.97* 
45 82.17 7.11 81.29 6.60 0.54 68 0.59* 
60 81.74 6.84 82.14 6.36 0.25 68 0.80* 
75 82.09 6.48 81.83 6.05 0.17 68 0.86* 
90 82.91 5.85 82.74 5.59 0.13 68 0.90* 
105 87.57 6.94 85.71 6.28 1.17 68 0.25* 
110 88.04 7.53 89.06 6.95 0.52 52 0.61* 
115 91.75 7.13 94.00 7.69 0.91 35 0.37* 
120 97.92 5.44 98.69 3.12 0.44 23 0.66* 
* Not Significant 
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COMPARISON OF PERCENTAGE DIFFERENCE BETWEEN 
INTRAOPERATIVE MEAN ARTERIAL PRESSURE AND 
BASELINE MEAN ARTERIAL PRESSURE  
CHART-9 
 
The mean arterial pressure of Desflurane group as well as 
Sevoflurane group noted at induction, at 5 (post intubation) and 10 
minutes, and post extubation all lie within 20 percent range from mean 
baseline mean arterial pressure. The percentage difference at each stage 
compared to baseline in both groups were similar. 
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TABLE-11 
 
DESFLURANE SEVOFLURANE 
Time Mean SD 
Mean 
difference 
from 
baseline 
Percentage 
difference 
from 
baseline 
Mean SD 
Mean 
difference 
from 
baseline 
Percentage 
difference 
from 
baseline 
Baseline 90.14 6.92 - - 91.91 6.25 - - 
Induction 81.49 8.23 -8.65 9.6 82.49 7.8 -9.42 10.25 
5 minutes 85.83 8.13 -4.31 4.78 82.37 8.04 -9.54 10.38 
10 minutes 80.06 6.83 -10.08 11.18 79.6 8.96 -12.31 13.39 
Post 
extubation 
96.43 5.07 6.26 6.94 98 4.94 6.09 6.63 
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DURATION OF SURGERY 
CHART-10 
 
TABLE-12 
GROUP-D GROUP-S 
t-value Df p-value 
MEAN SD MEAN SD 
106.60 6.44 103.94 5.14 1.91 68 0.06* 
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POST-OPERATIVE RECOVERY CHARACTERISTICS 
TIME TO SPONTANEOUS MOVEMENT 
TABLE-13 
GROUP-D GROUP-S t-value Df p-value 
MEAN SD MEAN SD 
3.97 0.71 7.17 0.79 17.92 68 0.001 
 
 Time to spontaneous movement in the desflurane group was 3.97 
+0.71 minutes whereas it was 7.17+0.79 minutes in the sevoflurane 
group. This difference was statistically significant. 
TIME TO RESPONSE TO PAIN 
TABLE-14 
GROUP-D GROUP-S t-value Df p-value 
MEAN SD MEAN SD 
5.40 0.88 8.57 0.92 14.76 68 0.001 
 
Time to response to pain in the sevoflurane group (8.57 + 0.92 
minutes) was significantly (p = 0.001) higher than that in the desflurane 
group (5.40 +0.88 minutes). This difference was statistically significant. 
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TIME TO EXTUBATION 
TABLE-15 
GROUP-D GROUP-S t-value df p-value 
MEAN SD MEAN SD 
6.54 0.85 10.49 1.07 17.08 68 0.001 
 
Time to extubation in desflurane group was 6.54 + 0.85 minutes 
when compared to sevoflurane group of 10.49 + 1.07 minutes. This 
difference in the mean time to extubation was statistically significant. 
TIME TO RECALL OF NAME 
TABLE-16 
GROUP-D GROUP-S t-value df p-value 
MEAN SD MEAN SD 
7.91 0.82 12.37 1.19 18.26 68 0.001 
 
Patients in the desflurane group were able to recall their name in 
7.91 +0.82 minutes. But those in the sevoflurane group were able to recall 
their name only after 12.37 +1.19 minutes. This difference was 
statistically significant (p = 0.001). 
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TIME TO HAND GRIP 
TABLE-17 
GROUP-D GROUP-S t-value df p-value 
MEAN SD MEAN SD 
9.31 0.87 14.23 1.29 18.75 68 0.001 
 
Time to hand grip in desflurane group was 9.31 +0.87 minutes and 
in sevoflurane group was 14.23 +1.29 minutes. There existed statistically 
significant difference between the two groups. (p=0.001) 
TIME TO ACHIEVE PARS ≥10 
TABLE-18 
GROUP-D GROUP-S t-value df p-value 
MEAN SD MEAN SD 
10.51 0.89 16.69 1.47 21.26 68 0.001 
 
Patients in the desflurane group achieved PARS ≥ 10 at 10.51 
+0.89 minutes whereas the patients in the sevoflurane group were able to 
achieve it only after 16.69 +1.47 minutes. This difference was statistically 
significant (p < 0.05). 
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CHART-11 
 
TABLE-19 
RECOVERY 
CHARACTERISTICS 
GROUP-D GROUP-S t-
value 
df 
P-
value Mean Sd Mean Sd 
TIME TO 
SPONTANEOUS 
MOVEMEN 
3.97 0.71 7.17 0.79 17.92 68 0.001 
TIME TO RESPONSE TO 
PAIN 
5.40 0.88 8.57 0.92 14.76 68 0.001 
TIME TO EXTUBATION 6.54 0.85 10.49 1.07 17.08 68 0.001 
TIME TO RECALL OF 
NAME 
7.91 0.82 12.37 1.19 18.26 68 0.001 
TIME TO HAND GRIP 9.31 0.87 14.23 1.29 18.75 68 0.001 
TIME TO ACHIEVE 
PARS ≥10 
10.51 0.89 16.69 1.47 21.26 68 0.001 
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DISCUSSION 
General anesthesia is a medically induced state of loss of 
consciousness, analgesia, along with loss of protective reflexes and 
induced immobility, resulting from administration of general anesthetic 
agents. With the introduction of less soluble volatile anesthetics which 
provides amnesia, maintain hemodynamics and promote early recovery, 
makes general anesthesia the technique of choice for many patients. 
In this study, 70 PS-ASA I-II patients who underwent elective 
thyroidectomy surgery under general anesthesia, were compared of their 
intraoperative hemodynamics, postoperative emergence and recovery 
characteristics of sevoflurane with that of desflurane in nitrous oxide 
anesthesia. 
Hemodynamic profile 
The preoperative heart rate (HR) and mean arterial pressure 
(MAP), before any medication given, was considered as the baseline HR 
and MAP. The HR and MAP of desflurane group was compared with that 
of sevoflurane group at regular intervals. Also HR and MAP noted in 
each group at regular interval was compared with the baseline value of 
that respective group and the percentage difference from mean baseline 
74 
 
was noted. This percentage difference from baseline of desflurane and 
sevoflurane was then compared between them. And it was found out that 
the HR and MAP of desflurane and sevoflurane group were comparable 
and the difference was insignificant (p value > 0.05). Both the desflurane 
and sevoflurane maintained the hemodynamics within 20% of the 
baseline values. 
No rescue doses of Fentanyl were required for maintaining 
hemodynamics in both groups.  
Hypotension was easily managed with fluid replacement and none 
of the patients were excluded in both the groups. 
The volatile agent was stopped after the last skin suture at the end 
of the surgery and the recovery parameters evaluated at each minute 
interval. 
The time to spontaneous movement, response to pain, time to 
extubation, recall of name, and hand grip were shorter in the desflurane 
group compared to sevoflurane group. Post anesthesia recovery score of 
Aldrete and Kroulik greater than or equal to 10 was achieved earlier in 
the desflurane group.  
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In the desflurane group, patient moved their limbs in a mean time 
of 3.97 + 0.71 minutes after the discontinuation of the anesthetics 
whereas it took a mean of 7.17 + 0.79 minutes in the sevoflurane group. 
The time to response to pain was achieved in a mean time of 5.4 + 
0.88 minutes in the desflurane group whereas in the sevoflurane group it 
took a mean of 8.57 + 0.92 minutes. 
The patients in the desflurane group were extubated earlier than 
those in the sevoflurane group. The patients in the desflurane group were 
able to recall their names in a mean time of 7.91 + 0.82 minutes whereas 
those in the sevoflurane group took 12.37 + 1.19 minutes. 
The time to hand grip was achieved earlier in the desflurane group 
(9.31+0.87 minutes), whereas for Sevoflurane, it took 14.23+1.29 
minutes. 
The post anesthesia recovery score of greater than 10 (PARS>10) 
was achieved in a mean of 10.51 + 0.89 minutes in desflurane group 
which was earlier than sevoflurane (16.69+1.47 minutes)  
The study by Nathanson et al. suggested that sevoflurane and 
desflurane provided similar intraoperative conditions during the 
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maintenance period. Although recovery was more rapid after desflurane, 
there was no difference in later recovery end-points.
25 
Metaanalysis, conducted by Macario A et al, of 22 studies done on 
a total of 746 patients who revieved sevoflurane and 752 who received 
desflurane were compared about their postoperative recovery 
characteristics. It was found out that the patients receiving desflurane 
followed commands, were extubated, and were oriented 1.0-1.2 minutes 
earlier than those receiving sevoflurane.
26 
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SUMMARY 
The aim of this study is to prospectively compare the 
hemodynamic, emergence and recovery characteristics of sevoflurane 
with that of desflurane in general anesthesia for thyroidectomy cases. 70 
ASA I and II patients undergoing elective thyroidectomy procedures less 
than 2 hours duration under endotracheal general anesthesia were 
randomly divided into two groups. Both the groups were induced with 
standard intravenous induction technique. Group D was maintained with 
6% desflurane and group S with 2% sevoflurane in 30% oxygen with 
70% nitrous oxide. Injection fentanyl 0.5µg/kg was repeated every 30 
minutes. Injection vecuronium 0.02mg/kg was repeated every 30 minutes. 
Mean arterial pressure and heart rate were noted before induction, during 
induction and every 5 minutes after induction. If there is any increase in 
the mean arterial pressure and heart rate more than 20% of the 
preinduction values, an additional dose of injection fentanyl 1µg/kg was 
given. If there is any reduction in the mean arterial pressure more than 
20% from the baseline value, it was treated with bolus of intravenous 
fluids and replacement of intraoperative blood loss. When the 
hemodynamics of the patient was unresponsive to the above measures, 
the patient was excluded from the study. Nitrous oxide and volatile 
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anesthetic were discontinued after the last skin suture. Residual 
neuromuscular blockade was reversed with injection neostigmine 
40µg/kg and injection glycopyrrolate 10µg/kg intravenously.  
The time of discontinuation of anesthetic agents were noted as time 
zero for all the subsequent measurements and recovery times were 
determined at 1-minute intervals to awakening. 
Number of additional doses of fentanyl needed was noted. 
TIME TO  
 1.  First spontaneous movement 
  2.  Response to painful pinch 
  3.  Extubation 
  4.  Recall of name 
  5.  Hand grip 
  6.  Achieve a PARS ≥ 10 (post anesthesia recovery score of  
    Aldrete and Kroulik) were noted. 
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The following results were obtained. Of the two groups compared, 
1. Age, sex, weight and the duration of surgery were comparable in 
both the groups. 
2. Both desflurane and sevoflurane maintained hemodynamics and 
the difference was statistically insignificant. 
3. The time to first spontaneous movement, response to pain, 
extubation, recall of name, and hand grip were shorter in the 
desflurane group than the sevoflurane group. The difference was 
statistically significant. 
4. The time to achieve a PARS ≥10 was earlier in the desflurane 
group and it was statistically significant. 
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CONCLUSION 
The study results convey that, for intraoperative maintenance of 
general anaesthesia, both Desflurane and Sevoflurane provided similar 
hemodynamic changes and within normal limits. However the recovery 
and emergence from general anaesthesia was more rapid after Desflurane 
than Sevoflurane anaesthesia. 
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PATIENT CONSENT FORM 
Study Title 
 A Prospective randomized study on comparison of intraoperative 
hemodynamic stability and postoperative recovery characteristics of 
Sevoflurane with Desflurane in patients undergoing general anaesthesia 
for elective thyroid surgery.  
Study centre: ESIC MC & PGIMSR, K.K. Nagar, Chennai – 78 
Participant Name:      Age:  Sex: 
 I confirm that I have understood the purpose of procedure for the 
above study. I have the opportunity to ask the question and all my 
questions and doubts have been answered to my satisfaction. I understand 
that Desflurane or Sevoflurane will be administered to me for providing 
anaesthesia to undergo the surgery and for conducting research. I have 
been explained that the anesthetic technique is a standard and approved 
technique. I have been explained about the safety, advantage and 
disadvantage of the technique. I have been explained about the pitfall in 
the procedure. I understand that my participation in the study is voluntary 
and I am free to withdraw at anytime without giving any reason. I 
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understand that the investigator, regulatory authorities and the ethics 
committee will not need my permission to look at my health records both 
in respect to current study and any further research that may be conduced 
in relation to it, even if I withdraw from the study. I understand that my 
identity will not be revealed in any information released to third parties or 
published, unless as required under the law. I agree not to restrict the use 
of any data or results that arise from the study. I consent to undergo this 
procedure. 
Insurance No. : 
Date   :   Signature /Thumb impression of patient 
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1. GÚUS AÖøÁ ]Qaø\ø¯ ö\´²©õÖ ©¸zxÁº ©ØÖ® 
SÊÂÚøµ ÷ÁsiUöPõÒQ÷Óß. 
2. ÷{õ°ß ußø©  : 
]Qaø\ ¬øÓ  : 
CøÁ AøÚzx® GÚUS ©¸zxÁº -»® öuÎÁõP 
ÂÍUP¨£mhÚ. 
3. GÚUS ¬Ê ©¯UPzvß ÷£õx ^÷Áõ¨Ð¶ß  (Servoflurane) 
öhì¨Ð¶ß (Desflurane) GßÓ vµÁ Áõ² ©¯UP ©¸¢x öPõkzx  
AÖøÁ ]Qaø\ ©ØÖ® B´Ä ö\´x öPõÒÍ \®©vUQ÷Óß. 
4. CÁØÔß ªßÂøÍÄPøÍ ©¸zxÁº -»® AÔ¢xöPõs÷hß. 
5. AøÚzx ©¸zxÁ ]Qaø\ ¬øÓPÎß |øÓPÐ®  SøÓPÐ® 
GÚUS ÂÍUP¨£mhÚ. 
6. ÷©÷» öPõkUP£mkÒÍAøÚzx®©¸zxÁ©øÚ {ßöÚÔ  
(Ethics) SÊÂß Áøµ¬øÓUS Em£m÷h {hUS® GÚ ©¸zxÁº 
ÂÍUQÚõº.  ÷©¾® C¢u ]Qaø\ ¬øÓPÐUS Ehß£h 
©ÖUPÄ® GÚUS E¶ø© Esk Gß£øu {õß AÔ÷Áß. 
7. Gß ]Qaø\°ß÷£õx QøhUS® uPÁÀPøÍ ©¸zxÁ 
Bµõ´a]US £¯ß£kzuÄ® \®©u® AÎUQ÷Óß. 
{õß C¢u J¨¦uÀ £iÁzøu £izhu ¤ßÚ÷µ / £izxU 
Põs¤UP¨£mh  ¤ßÚ÷µ, Cuß \õµõ®\zøu ¬ÊÁx©õP ¦¶¢x 
öPõsh ¤ß÷£ ¬Ê©Úxhß \®©vzx øPö¯ÊzvkQß÷Óß. 
 
\õm]     J¨¦uÀ AÎ¨£Áº............................... 
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PROFORMA 
          Date: 
   
Name of the patient:  Age:   Sex: 
Insurance No:   Blood Group:  Wt:  Ht: 
Diagnosis: 
Procedure: 
Anaesthetic plan: 
PREOPERATIVE  DETAILS 
 
ASA Grade 
 
Remarks  
 
PREOP: 
 PR  NIBP  SpO2  Temp.  RR 
 CVS    RS 
 Airway Assessment 
INTRAOPERATIVE  DETAILS 
Premedication: 
Preoxygenation: 
Induction: 
Muscle Relaxant: 
Intubation: 
Ventillation: 
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TIME 
(Min) 
Basal Intubation 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100 105 110 115 120 
HR 
(/min) 
                          
SBP 
(mmHg) 
                          
DBP 
(mmHg) 
                          
MAP 
(mmHg) 
                          
SpO2                           
EtCO2                           
DRUGS  
                           
                           
                           
                           
                           
                           
IVF/Blood/ 
Colloid  
                          
Urine 
Output 
                          
Blood Loss                           
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Parameters observed 
 
Duration of surgery 
 
Parameter Time in minutes (from 
discontinuation of volatile agent) 
Time to spontaneous movement  
Time to response to pain  
Time to extubation  
Time to recall of name  
Time to hand grip  
Time to achieve PARS >10  
 
 
Signature of  Anesthetist 
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1 D SARASWATHAMMA 35 F 62 MULTINODULAR GOITRE SUBTOTAL THYROIDECTOMY 2 87 82 92 88 83 76 74 76 75 72 77 74 86 94 94 92 84 80 82 83 84 84 87 83 86 86 85 87 97 97 102 4 5 8 9 11 11
2 D SARAVANAN 43 M 58 LEFT COLLOID GOITRE LEFT HEMITHYROIDECTOMY 1 74 88 78 71 69 70 68 77 65 66 67 68 89 89 84 76 79 77 77 76 76 75 77 79 78 82 91 91 99 3 5 6 7 9 10
3 D SHANMUGHAPRIYA 32 F 57 MULTINODULAR GOITRE SUBTOTAL THYROIDECTOMY 1 71 66 74 71 71 70 68 69 69 70 65 64 89 89 93 85 87 85 83 82 82 79 81 78 80 74 87 87 98 4 4 7 8 10 12
4 D RAMESH 40 M 60 RIGHT COLLOID GOITRE RIGHT HEMITHYROIDECTOMY 2 75 77 79 78 75 75 76 73 69 67 69 76 77 84 94 94 101 95 99 89 87 87 86 86 90 90 90 85 88 89 102 102 108 4 6 7 8 11 11
5 D SARALA 36 F 57 RIGHT COLLOID GOITRE RIGHT HEMITHYROIDECTOMY 1 88 80 86 85 83 82 82 81 79 89 86 95 90 89 93 105 105 90 78 79 78 78 78 77 75 77 74 73 79 77 79 84 92 92 112 5 7 8 9 11 12
6 D TAMILMANUI 25 F 55 LEFT COLLOID GOITRE LEFT HEMITHYROIDECTOMY 1 92 86 88 84 85 83 83 83 81 79 76 78 92 98 98 87 76 79 82 82 81 81 80 81 76 75 75 87 95 95 104 5 5 6 8 9 10
7 D PARVATHI 39 F 51 MULTINODULAR GOITRE SUBTOTAL THYROIDECTOMY 2 80 71 84 85 79 78 77 77 75 80 72 72 90 90 88 76 80 75 74 74 74 75 74 81 75 74 95 95 98 5 7 7 8 9 11
8 D RANGANAYAKI 50 F 60 MULTINODULAR GOITRE SUBTOTAL THYROIDECTOMY 2 76 74 84 76 75 73 71 71 70 70 70 68 69 70 81 90 90 90 79 89 87 85 83 83 81 86 79 88 85 84 85 92 99 99 115 3 4 5 7 8 9
9 D SAITHAMMAL 56 F 60 RIGHT COLLOID GOITRE RIGHT HEMITHYROIDECTOMY 2 94 81 90 88 84 83 85 80 76 84 80 85 92 92 104 91 95 89 89 86 88 88 85 90 86 90 99 99 97 4 5 8 9 11 11
10 D KRITHIKA 26 F 55 LEFT COLLOID GOITRE LEFT HEMITHYROIDECTOMY 1 88 89 95 89 96 80 76 77 80 90 81 78 76 78 85 91 91 93 91 88 79 79 83 82 82 80 93 90 83 83 86 91 98 98 115 4 4 5 6 8 9
11 D SUGANYA 30 F 63 MULTINODULAR GOITRE SUBTOTAL THYROIDECTOMY 1 89 92 97 95 90 89 86 86 85 87 86 87 89 91 99 99 97 95 105 101 99 100 97 95 97 91 89 93 91 97 106 106 108 4 6 7 8 9 10
12 D SHANKARI 47 F 62 MULTINODULAR GOITRE SUBTOTAL THYROIDECTOMY 2 79 70 83 84 79 77 77 77 73 79 83 83 88 88 89 99 99 99 98 96 95 95 93 94 88 94 82 97 94 95 94 97 107 107 112 5 7 8 9 10 11
13 D ILAKKIYAMATHI 26 F 65 RIGHT COLLOID GOITRE RIGHT HEMITHYROIDECTOMY 1 91 85 90 86 84 82 82 83 79 87 75 81 95 95 94 90 95 94 92 92 89 88 88 89 84 84 95 95 109 4 5 6 8 9 11
14 D NEELAVATHI 28 F 57 LEFT COLLOID GOITRE LEFT HEMITHYROIDECTOMY 1 84 76 79 80 85 80 75 76 78 75 75 79 87 87 90 83 86 83 82 84 84 84 81 84 85 90 99 99 108 4 6 7 8 9 11
15 D DAIVANAYAKI 58 F 55 RIGHT COLLOID GOITRE RIGHT HEMITHYROIDECTOMY 2 78 70 66 63 64 61 68 68 67 64 68 65 76 79 80 87 87 89 79 78 78 76 76 76 75 75 75 78 79 78 78 81 88 88 114 4 5 6 8 9 11
16 D ILAVARASI 45 F 59 RIGHT COLLOID GOITRE RIGHT HEMITHYROIDECTOMY 1 81 74 84 84 82 76 74 73 76 75 74 80 88 91 91 90 84 93 90 87 84 80 81 83 82 82 86 88 95 95 103 5 6 7 9 10 12
17 D MEENA 35 F 65 MULTINODULAR GOITRE SUBTOTAL THYROIDECTOMY 2 87 80 89 84 85 82 82 83 82 79 81 80 83 99 99 90 81 86 87 87 87 89 89 87 87 86 89 91 101 101 104 3 5 6 8 9 10
18 D MURUGAN 56 M 65 RIGHT COLLOID GOITRE RIGHT HEMITHYROIDECTOMY 2 78 69 79 75 74 72 71 72 69 84 72 73 73 77 89 97 97 94 88 96 90 89 89 87 88 89 86 87 89 89 90 91 106 106 113 4 5 7 8 10 11
19 D JHANSI RANI 23 F 55 MULTINODULAR GOITRE SUBTOTAL THYROIDECTOMY 1 92 76 88 85 84 82 80 79 80 81 80 80 89 89 74 66 74 72 72 71 70 70 71 70 70 76 88 88 99 4 6 6 7 9 10
20 D BASANTI 28 F 60 LEFT COLLOID GOITRE LEFT HEMITHYROIDECTOMY 1 88 75 80 82 80 78 77 75 76 78 77 76 90 90 77 70 74 74 74 75 74 75 76 75 76 77 92 92 98 5 6 7 9 10 11
21 D VALLI 38 F 63 MULTINODULAR GOITRE SUBTOTAL THYROIDECTOMY 1 85 77 88 85 83 81 80 80 79 78 80 81 79 78 82 94 94 90 81 87 86 84 85 85 85 87 89 85 86 87 87 89 99 99 114 3 4 6 7 8 9
22 D RAJESH 27 M 72 LEFT COLLOID GOITRE LEFT HEMITHYROIDECTOMY 1 82 70 76 74 73 75 73 73 70 71 71 79 83 89 89 79 70 76 74 74 74 75 73 75 77 76 82 82 89 89 104 4 5 6 8 9 10
23 D RAMU 48 M 62 LEFT COLLOID GOITRE LEFT HEMITHYROIDECTOMY 1 80 70 78 73 70 69 67 69 69 67 66 68 69 72 84 91 91 92 81 87 85 85 83 82 82 82 81 81 81 80 83 94 100 100 113 4 6 7 8 10 11
24 D GOVINDASAMY 46 M 64 LEFT COLLOID GOITRE LEFT HEMITHYROIDECTOMY 1 74 65 70 69 68 68 69 67 65 66 64 67 82 82 97 86 92 87 86 86 85 86 88 89 89 85 99 99 99 4 5 6 7 9 10
25 D GEETHA 37 F 57 MULTINODULAR GOITRE SUBTOTAL THYROIDECTOMY 2 79 70 78 77 75 75 76 75 77 79 79 82 82 86 85 96 96 85 80 86 83 83 83 82 84 81 79 78 80 79 79 83 99 99 114 3 5 6 8 9 10
26 D TAMARAISELVI 54 F 65 LEFT COLLOID GOITRE LEFT HEMITHYROIDECTOMY 1 88 75 79 83 82 80 81 79 83 83 84 92 88 91 98 98 99 84 89 92 90 90 90 91 87 82 80 92 86 88 101 101 109 3 5 6 7 8 9
27 D BUDHAMAI 42 M 62 RIGHT COLLOID GOITRE RIGHT HEMITHYROIDECTOMY 1 80 71 82 85 84 82 80 80 79 79 80 79 82 92 92 99 87 93 90 90 90 93 92 89 87 89 84 84 97 97 103 5 6 7 8 10 11
28 D GANESH 24 M 59 LEFT COLLOID GOITRE LEFT HEMITHYROIDECTOMY 1 78 70 73 75 75 78 77 77 75 74 77 72 93 93 88 77 79 77 76 76 76 74 77 77 76 77 90 90 99 4 6 6 7 9 10
29 D PRAKASH 48 M 70 RIGHT COLLOID GOITRE RIGHT HEMITHYROIDECTOMY 1 74 65 78 82 79 79 76 76 77 82 71 70 73 87 92 92 81 70 74 75 72 72 71 71 68 69 73 76 76 84 94 94 109 3 5 6 7 9 10
30 D LATHAMARY 36 F 54 MULTINODULAR GOITRE SUBTOTAL THYROIDECTOMY 2 85 77 89 87 87 85 86 86 87 89 83 86 83 85 90 95 95 91 80 83 85 84 84 84 85 83 80 85 83 85 83 90 98 98 114 4 5 6 7 9 10
31 D SOKKAMMAL 55 F 58 MULTINODULAR GOITRE SUBTOTAL THYROIDECTOMY 2 77 64 78 74 75 75 76 75 74 74 75 77 77 76 81 89 89 85 70 75 74 75 75 76 76 74 72 73 74 72 73 84 92 92 112 5 7 8 9 10 12
32 D VEERARAGAVAN 53 M 60 LEFT COLLOID GOITRE LEFT HEMITHYROIDECTOMY 2 82 79 81 79 84 83 85 87 87 87 86 87 94 94 90 86 85 87 88 88 88 89 91 93 90 89 99 99 98 4 6 7 9 9 11
33 D JOTHIRAMAN 37 M 67 LEFT COLLOID GOITRE LEFT HEMITHYROIDECTOMY 1 84 74 77 74 75 72 72 70 76 78 78 81 80 94 94 98 93 96 97 96 96 94 94 92 90 87 89 89 96 96 115 3 4 5 7 8 9
34 D BANUPRIYA 24 F 57 RIGHT COLLOID GOITRE RIGHT HEMITHYROIDECTOMY 1 79 68 74 73 70 70 70 72 72 73 69 70 74 74 85 92 92 81 72 88 86 84 83 83 83 77 78 81 78 80 80 89 97 97 113 4 6 7 9 9 11
35 D RAFI 35 M 54 RIGHT COLLOID GOITRE RIGHT HEMITHYROIDECTOMY 1 91 80 84 79 77 78 79 81 79 81 82 83 94 94 84 70 76 73 70 71 71 72 70 71 75 77 93 93 99 3 5 6 8 9 11
82.57142857 75.31428571 82 80.1 79 77 77 77 76 78 76 78 84 85.3 87.9 94 92.85714286 90.142857 81.48571429 86 84 83 83 83 82 82 82 82 83 88 88 92 98 96.428571
36 S RAJESHWARI 40 F 74 MULTINODULAR GOITRE SUBTOTAL THYROIDECTOMY 2 80 81 78 72 69 69 68 73 64 69 68 67 72 89 89 87 81 84 79 79 80 82 78 75 75 78 77 80 89 89 99 8 10 11 12 13 16
37 S VELAMMAL 36 F 56 LEFT COLLOID GOITRE LEFT HEMITHYROIDECTOMY 2 94 86 95 97 93 89 90 87 80 80 76 77 85 89 99 99 97 90 99 99 97 96 96 95 96 93 89 88 88 92 104 104 105 6 8 10 11 13 14
38 S VINOD 27 M 75 LEFT COLLOID GOITRE LEFT HEMITHYROIDECTOMY 1 82 74 79 77 76 78 74 76 70 82 70 77 82 90 90 89 76 78 78 81 80 78 78 76 77 75 82 84 91 91 99 7 8 11 13 14 16
39 S LALITHA 33 F 60 RIGHT COLLOID GOITRE RIGHT HEMITHYROIDECTOMY 2 69 60 68 66 65 65 67 66 64 65 74 76 88 88 92 83 89 85 84 83 83 80 76 77 74 76 90 90 97 6 7 8 10 12 14
40 S MANIVANNAN 35 M 64 RIGHT COLLOID GOITRE RIGHT HEMITHYROIDECTOMY 2 78 74 78 72 70 70 70 68 68 68 65 64 88 89 93 93 85 72 74 70 71 72 72 72 72 72 75 79 80 89 98 98 105 7 8 10 11 13 15
41 S SARALA 36 F 60 PAPILLARY CARCINOMA SUBTOTAL THYROIDECTOMY 2 75 65 74 75 71 68 65 64 66 79 84 87 71 76 80 94 94 84 74 81 79 79 78 78 79 80 83 84 80 79 80 89 97 97 111 6 7 9 10 12 14
42 S GEETHARANI 29 F 58 LEFT COLLOID GOITRE LEFT HEMITHYROIDECTOMY 1 92 76 85 79 76 77 77 74 68 68 71 74 77 89 89 94 88 90 91 86 80 79 79 78 81 85 87 90 97 97 100 8 9 10 11 13 16
43 S SHANTHI 45 F 60 PAPILLARY CARCINOMA SUBTOTAL THYROIDECTOMY 2 78 76 89 87 84 82 83 83 79 87 79 75 78 77 89 95 95 101 93 99 99 97 97 96 96 86 93 86 87 86 88 90 99 99 110 7 8 10 12 14 16
44 S MURUGAN 55 M 57 MULTINODULAR GOITRE SUBTOTAL THYROIDECTOMY 2 96 85 94 90 89 89 87 88 92 93 91 89 92 91 92 105 105 97 80 87 83 82 83 84 84 85 87 87 89 88 89 95 105 105 110 7 8 10 13 15 17
45 S BHANUMATHY 57 F 63 RIGHT COLLOID GOITRE RIGHT HEMITHYROIDECTOMY 1 80 74 77 79 75 82 83 79 71 74 68 76 77 84 93 93 99 93 104 101 99 99 98 96 93 91 92 92 93 95 100 100 105 7 9 10 12 14 16
46 S RANI 43 F 56 LEFT COLLOID GOITRE LEFT HEMITHYROIDECTOMY 1 89 76 88 86 89 92 90 95 89 85 85 85 92 98 98 96 82 90 88 87 85 85 85 81 84 85 87 90 97 97 99 7 9 11 12 14 16
47 S NELAVENI 27 F 58 MULTINODULAR GOITRE SUBTOTAL THYROIDECTOMY 1 95 92 108 111 104 98 94 93 92 98 87 90 83 86 98 109 109 102 99 104 101 101 100 97 94 97 94 94 94 95 97 107 107 111 6 8 9 11 13 15
48 S SIVARAMAN 41 M 56 RIGHT COLLOID GOITRE RIGHT HEMITHYROIDECTOMY 1 88 80 85 78 79 80 83 84 84 85 80 81 83 99 99 94 91 93 91 91 90 90 89 86 88 88 87 88 98 98 99 8 9 11 14 16 18
49 S DASAMMAL 58 F 59 LEFT COLLOID GOITRE LEFT HEMITHYROIDECTOMY 2 70 62 74 74 70 69 68 65 67 65 63 78 86 86 97 90 93 89 88 86 85 85 84 83 82 85 96 96 97 6 7 8 10 12 14
50 S SHAHEENA MARY 48 F 58 MULTINODULAR GOITRE SUBTOTAL THYROIDECTOMY 2 92 82 89 86 87 85 89 88 86 94 83 85 83 90 99 99 105 97 103 99 98 96 96 96 93 94 94 89 89 92 110 110 105 7 9 10 12 14 17
51 S ABHIRAMI 33 F 64 LEFT COLLOID GOITRE LEFT HEMITHYROIDECTOMY 1 79 70 82 72 76 75 77 77 76 75 76 76 78 82 90 94 94 100 92 98 89 88 87 87 87 90 87 87 89 88 88 89 96 96 108 7 9 12 13 15 17
52 S HARIKUMAR 44 F 59 RIGHT COLLOID GOITRE RIGHT HEMITHYROIDECTOMY 2 78 66 71 70 68 67 68 65 68 66 65 68 68 77 82 90 90 88 80 83 82 78 75 75 74 78 76 75 78 80 81 93 104 104 109 8 9 11 13 14 17
53 S ANBUSELVAM 23 M 64 LEFT COLLOID GOITRE LEFT HEMITHYROIDECTOMY 1 76 68 69 72 69 68 66 67 68 67 62 67 66 72 80 80 88 78 80 76 74 73 72 72 74 76 74 74 75 79 89 89 104 8 9 11 13 15 18
54 S SIVASAMI 56 M 70 RIGHT COLLOID GOITRE RIGHT HEMITHYROIDECTOMY 2 74 70 77 68 65 67 65 64 61 77 68 65 68 69 71 79 79 92 87 93 88 85 83 82 84 83 87 85 84 82 84 92 98 98 108 8 11 12 14 17 19
55 S DEEPA 34 F 60 MULTINODULAR GOITRE SUBTOTAL THYROIDECTOMY 1 85 74 79 72 71 75 78 73 68 73 72 70 75 77 88 94 94 94 82 90 85 83 82 81 80 79 75 79 82 82 83 87 98 98 110 7 8 10 13 15 18
56 S SHALINI 41 F 58 RIGHT COLLOID GOITRE RIGHT HEMITHYROIDECTOMY 2 76 73 78 72 68 67 64 62 65 72 71 76 84 90 90 85 77 79 78 74 75 74 76 77 79 79 87 89 95 95 99 8 9 11 14 16 19
57 S SHANTHA 46 F 63 MULTINODULAR GOITRE SUBTOTAL THYROIDECTOMY 2 93 79 86 85 82 89 83 82 79 83 78 87 84 89 96 96 102 90 93 89 88 87 88 89 84 86 85 85 85 94 109 109 105 7 8 10 12 13 16
58 S DEENADAYALAM 42 M 70 RIGHT COLLOID GOITRE RIGHT HEMITHYROIDECTOMY 1 77 68 82 79 74 70 69 68 69 70 72 86 90 94 94 89 80 82 80 75 74 76 75 77 75 76 88 92 97 97 99 7 9 11 13 15 17
59 S GANDHIMATHI 50 F 63 MULTINODULAR GOITRE SUBTOTAL THYROIDECTOMY 2 89 76 85 80 79 74 75 74 73 69 76 70 79 80 89 96 96 90 79 85 82 79 79 80 81 78 79 81 76 81 81 87 97 97 110 7 8 10 12 14 17
60 S MANIKANDAN 28 M 60 RIGHT COLLOID GOITRE RIGHT HEMITHYROIDECTOMY 1 80 69 78 73 74 70 69 68 70 83 70 71 86 95 95 92 85 90 85 83 82 82 83 79 86 83 82 90 96 96 98 8 9 12 14 17 19
61 S LOKANATHAN 42 M 58 RIGHT COLLOID GOITRE RIGHT HEMITHYROIDECTOMY 1 84 69 78 73 72 75 71 70 73 71 74 69 91 91 84 72 81 80 80 78 78 78 76 75 74 73 98 98 95 7 9 10 12 14 17
62 S REVATHY 34 F 65 LEFT COLLOID GOITRE LEFT HEMITHYROIDECTOMY 1 92 78 84 80 79 74 75 72 74 70 69 74 76 79 86 101 101 87 70 72 76 75 75 73 73 74 77 76 76 77 79 87 96 96 108 7 9 12 13 15 17
63 S MURALI 58 M 59 MULTINODULAR GOITRE SUBTOTAL THYROIDECTOMY 2 76 65 79 73 72 70 69 69 68 66 65 70 79 88 88 88 70 74 78 77 75 75 75 75 77 77 78 86 99 99 99 8 9 11 13 14 17
64 S KAVITHA 35 F 60 PAPILLARY CARCINOMA SUBTOTAL THYROIDECTOMY 2 94 86 90 87 85 84 84 84 87 85 85 78 84 90 99 99 79 70 83 79 77 75 75 76 77 76 75 75 72 85 95 95 105 7 8 10 12 14 17
65 S SUBASH CHANDRA BOSE 47 M 65 RIGHT COLLOID GOITRE RIGHT HEMITHYROIDECTOMY 1 88 74 86 82 81 79 78 78 78 74 73 82 77 79 87 95 95 89 77 79 78 75 75 78 78 75 80 83 80 84 84 88 94 94 108 9 10 12 14 16 18
66 S NAVACHANDRA BABU 57 M 58 MULTINODULAR GOITRE SUBTOTAL THYROIDECTOMY 2 81 75 73 79 85 84 82 82 84 76 77 70 70 73 85 95 95 97 84 88 88 89 89 89 88 90 87 85 86 87 88 90 101 101 109 8 9 11 13 15 18
67 S USHA 32 F 60 MULTINODULAR GOITRE SUBTOTAL THYROIDECTOMY 1 79 78 82 85 83 79 78 76 79 75 74 74 81 83 85 93 93 87 83 84 82 79 78 78 79 83 80 76 79 79 80 88 99 99 108 8 10 12 13 15 17
68 S ARIVUKARASI 26 F 70 RIGHT COLLOID GOITRE RIGHT HEMITHYROIDECTOMY 1 94 84 89 88 86 83 81 78 79 79 80 78 97 97 90 84 85 87 83 83 82 80 79 82 82 84 94 94 96 6 7 9 11 13 15
69 S GEETHA 36 F 55 LEFT COLLOID GOITRE LEFT HEMITHYROIDECTOMY 1 88 85 87 87 85 83 82 84 75 87 78 76 84 96 96 94 83 86 87 86 84 83 83 81 87 89 86 87 98 98 99 7 8 11 13 14 18
70 S SHANTHI 29 F 61 RIGHT COLLOID GOITRE RIGHT HEMITHYROIDECTOMY 1 93 79 87 80 83 84 83 84 79 83 78 73 77 83 90 96 96 83 75 80 84 82 82 81 79 78 76 75 75 76 76 87 99 99 109 6 8 11 14 15 19
83.82857143 75.11428571 82.4 79.6 78.1 77 77 76 75 77 74 76 80.9 85.3 89.1 95 93.85714286 91.914286 82.48571429 87 85 84 83 83 82 81 82 82 83 86 89 94 99 98
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